These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

677 related items for PubMed ID: 27454919

  • 1. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F, Rostaing L, Gugenheim J, Durand F, Radenne S, Leroy V, Neau-Cransac M, Calmus Y, Salamé E, Pageaux GP, Duvoux C, Taguieva N, Sinnasse-Raymond G, Sebagh M, Samuel D, Marquet P.
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [Abstract] [Full Text] [Related]

  • 2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 3. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
    van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD.
    Transplantation; 2008 Oct 27; 86(8):1043-51. PubMed ID: 18946341
    [Abstract] [Full Text] [Related]

  • 4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 27; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 5. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H, Takahara S, Amada N, Tomikawa S, Chikaraishi T, Takahashi K, Uchida K, Akiyama T, Tanabe K, Toma H, Study Group for the Antimetabolite Comparison of Trial (AMCT).
    Exp Clin Transplant; 2016 Oct 27; 14(5):518-525. PubMed ID: 27733107
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.
    Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280
    [Abstract] [Full Text] [Related]

  • 7. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
    Geng L, Wang LD, Huang JJ, Shen T, Wang ZY, Lin BY, Ye YF, Zheng SS.
    Hepatobiliary Pancreat Dis Int; 2018 Jun 15; 17(3):204-209. PubMed ID: 29807766
    [Abstract] [Full Text] [Related]

  • 8. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G, Glyda M, Albano L, Viklický O, Merville P, Tydén G, Mourad M, Lõhmus A, Witzke O, Christiaans MHL, Brown MW, Undre N, Kazeem G, Kuypers DRJ, Advagraf-based immunosuppression regimen examining new onset diabetes mellitus in kidney transplant recipients (ADVANCE) study investigators.
    Transplantation; 2017 Aug 15; 101(8):1924-1934. PubMed ID: 27547871
    [Abstract] [Full Text] [Related]

  • 9. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
    Squifflet JP, Bäckman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, Kunzendorf U, Heemann U, Land W, Morales JM, Mühlbacher F, Talbot D, Taube D, Tyden G, van Hooff J, Schleibner S, Vanrenterghem Y, European Tacrolimus-MMF Renal Study Group.
    Transplantation; 2001 Jul 15; 72(1):63-9. PubMed ID: 11468536
    [Abstract] [Full Text] [Related]

  • 10. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
    Gourishankar S, Houde I, Keown PA, Landsberg D, Cardella CJ, Barama AA, Dandavino R, Shoker A, Pirc L, Wrobel MM, Kiberd BA.
    Clin J Am Soc Nephrol; 2010 Jul 15; 5(7):1282-9. PubMed ID: 20498245
    [Abstract] [Full Text] [Related]

  • 11. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
    Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I.
    Transplantation; 1997 Dec 27; 64(12):1755-60. PubMed ID: 9422416
    [Abstract] [Full Text] [Related]

  • 12. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
    Chapman WC, Brown RS, Chavin KD, Sudan D, Koneru B, Junge G, Dong G, Patel D, Teperman L, Fung JJ.
    Transplantation; 2017 Feb 27; 101(2):341-349. PubMed ID: 28121741
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W, Huppertz A, Rath T, Ziefle S, Rump LC, Hansen A, Budde K, Lehner LJ, Shipkova M, Baeumer D, Kroeger I, Sieder C, Klein T, Schenker P.
    Transplantation; 2017 Nov 27; 101(11):2780-2788. PubMed ID: 28658202
    [Abstract] [Full Text] [Related]

  • 14. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
    Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, Duvoux C, Nevens F, Fung JJ, Dong G, Rauer B, Junge G, H2304 Study Group.
    Transplantation; 2015 Jul 27; 99(7):1455-62. PubMed ID: 26151607
    [Abstract] [Full Text] [Related]

  • 15. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
    Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD.
    Am J Transplant; 2009 Jul 27; 9(7):1607-19. PubMed ID: 19459794
    [Abstract] [Full Text] [Related]

  • 16. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
    Boillot O, Seket B, Dumortier J, Pittau G, Boucaud C, Bouffard Y, Scoazec JY.
    Liver Transpl; 2009 Nov 27; 15(11):1426-34. PubMed ID: 19877264
    [Abstract] [Full Text] [Related]

  • 17. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.
    Le Meur Y, Thierry A, Glowacki F, Rerolle JP, Garrigue V, Ouali N, Heng AE, Delahousse M, Albano L, Lang P, Couzi L, Jaureguy M, Lebranchu Y, Mousson C, Glotz D, Kessler M, Vrtovsnik F, Rouanet S, Tagieva N, Kamar N.
    Transplantation; 2011 Dec 15; 92(11):1244-51. PubMed ID: 22067312
    [Abstract] [Full Text] [Related]

  • 18.  Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key.
    Norero B, Serrano CA, Sanchez-Fueyo A, Duarte I, Torres J, Ocquetau M, Barrera F, Arrese M, Soza A, Benítez C.
    Ann Hepatol; 2011 Dec 15; 16(1):94-106. PubMed ID: 28051798
    [Abstract] [Full Text] [Related]

  • 19. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK, Klinger M, Vítko Š, Glyda M, Midtvedt K, Stefoni S, Citterio F, Pietruck F, Squifflet JP, Segoloni G, Krüger B, Sperschneider H, Banas B, Bäckman L, Weber M, Carmellini M, Perner F, Claesson K, Marcinkowski W, Ostrowski M, Senatorski G, Nordström J, Salmela K.
    Transplantation; 2012 Sep 15; 94(5):492-8. PubMed ID: 22858806
    [Abstract] [Full Text] [Related]

  • 20. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
    Rummo OO, Carmellini M, Rostaing L, Oberbauer R, Christiaans MH, Mousson C, Langer RM, Citterio F, Charpentier B, Brown M, Kazeem G, Lehner F, ADHERE study investigators.
    Transpl Int; 2017 Jan 15; 30(1):83-95. PubMed ID: 27754567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.